416 related articles for article (PubMed ID: 34885245)
1. Promising Antigens for the New Frontier of Targeted Immunotherapy in Multiple Myeloma.
Cho SF; Xing L; Anderson KC; Tai YT
Cancers (Basel); 2021 Dec; 13(23):. PubMed ID: 34885245
[TBL] [Abstract][Full Text] [Related]
2. Targeting B Cell Maturation Antigen (BCMA) in Multiple Myeloma: Potential Uses of BCMA-Based Immunotherapy.
Cho SF; Anderson KC; Tai YT
Front Immunol; 2018; 9():1821. PubMed ID: 30147690
[TBL] [Abstract][Full Text] [Related]
3. BCMA-Targeting Therapy: Driving a New Era of Immunotherapy in Multiple Myeloma.
Cho SF; Lin L; Xing L; Li Y; Yu T; Anderson KC; Tai YT
Cancers (Basel); 2020 Jun; 12(6):. PubMed ID: 32516895
[TBL] [Abstract][Full Text] [Related]
4. Immunotherapies targeting GPRC5D in relapsed or refractory multiple myeloma: latest updates from 2022 ASH Annual Meeting.
Xia J; Li Z; Xu K
J Hematol Oncol; 2023 Jun; 16(1):60. PubMed ID: 37277826
[TBL] [Abstract][Full Text] [Related]
5. B-cell maturation antigen (BCMA) in multiple myeloma: the new frontier of targeted therapies.
Sanchez L; Dardac A; Madduri D; Richard S; Richter J
Ther Adv Hematol; 2021; 12():2040620721989585. PubMed ID: 33796236
[TBL] [Abstract][Full Text] [Related]
6. Bispecific antibodies in multiple myeloma treatment: A journey in progress.
Cho SF; Yeh TJ; Anderson KC; Tai YT
Front Oncol; 2022; 12():1032775. PubMed ID: 36330495
[TBL] [Abstract][Full Text] [Related]
7. B cell maturation antigen (BCMA)-based immunotherapy for multiple myeloma.
Tai YT; Anderson KC
Expert Opin Biol Ther; 2019 Nov; 19(11):1143-1156. PubMed ID: 31277554
[No Abstract] [Full Text] [Related]
8. Role of Immunotherapy in Targeting the Bone Marrow Microenvironment in Multiple Myeloma: An Evolving Therapeutic Strategy.
Chung C
Pharmacotherapy; 2017 Jan; 37(1):129-143. PubMed ID: 27870103
[TBL] [Abstract][Full Text] [Related]
9. Targeting GPRC5D in multiple myeloma.
Elemian S; Al Hadidi S
Expert Rev Anticancer Ther; 2024 May; 24(5):229-238. PubMed ID: 38607646
[TBL] [Abstract][Full Text] [Related]
10. Monoclonal Antibody Therapies in Multiple Myeloma: A Challenge to Develop Novel Targets.
Nishida H; Yamada T
J Oncol; 2019; 2019():6084012. PubMed ID: 31781214
[TBL] [Abstract][Full Text] [Related]
11. T cell redirecting bispecific antibodies for multiple myeloma: emerging therapeutic strategies in a changing treatment landscape.
Kazandjian D; Kowalski A; Landgren O
Leuk Lymphoma; 2022 Dec; 63(13):3032-3043. PubMed ID: 36059239
[TBL] [Abstract][Full Text] [Related]
12. Hematologic Malignancies: Plasma Cell Disorders.
Dhodapkar MV; Borrello I; Cohen AD; Stadtmauer EA
Am Soc Clin Oncol Educ Book; 2017; 37():561-568. PubMed ID: 28561703
[TBL] [Abstract][Full Text] [Related]
13. Immunotherapeutic and Targeted Approaches in Multiple Myeloma.
Nadeem O; Tai YT; Anderson KC
Immunotargets Ther; 2020; 9():201-215. PubMed ID: 33117743
[TBL] [Abstract][Full Text] [Related]
14. GPRC5D is a target for the immunotherapy of multiple myeloma with rationally designed CAR T cells.
Smith EL; Harrington K; Staehr M; Masakayan R; Jones J; Long TJ; Ng KY; Ghoddusi M; Purdon TJ; Wang X; Do T; Pham MT; Brown JM; De Larrea CF; Olson E; Peguero E; Wang P; Liu H; Xu Y; Garrett-Thomson SC; Almo SC; Wendel HG; Riviere I; Liu C; Sather B; Brentjens RJ
Sci Transl Med; 2019 Mar; 11(485):. PubMed ID: 30918115
[TBL] [Abstract][Full Text] [Related]
15. A new decade: novel immunotherapies on the horizon for relapsed/refractory multiple myeloma.
Braunstein M; Weltz J; Davies F
Expert Rev Hematol; 2021 Apr; 14(4):377-389. PubMed ID: 33769179
[TBL] [Abstract][Full Text] [Related]
16. Patient selection for CAR T or BiTE therapy in multiple myeloma: Which treatment for each patient?
Kegyes D; Constantinescu C; Vrancken L; Rasche L; Gregoire C; Tigu B; Gulei D; Dima D; Tanase A; Einsele H; Ciurea S; Tomuleasa C; Caers J
J Hematol Oncol; 2022 Jun; 15(1):78. PubMed ID: 35672793
[TBL] [Abstract][Full Text] [Related]
17. Bispecific antibodies targeting BCMA, GPRC5D, and FcRH5 for multiple myeloma therapy: latest updates from ASCO 2023 Annual Meeting.
Zhao J; Ren Q; Liu X; Guo X; Song Y
J Hematol Oncol; 2023 Aug; 16(1):92. PubMed ID: 37537597
[TBL] [Abstract][Full Text] [Related]
18. Bispecific antibodies for the treatment of relapsed/refractory multiple myeloma: updates and future perspectives.
Parrondo RD; Ailawadhi S; Cerchione C
Front Oncol; 2024; 14():1394048. PubMed ID: 38660139
[TBL] [Abstract][Full Text] [Related]
19. Beyond BCMA: the next wave of CAR T cell therapy in multiple myeloma.
Miller K; Hashmi H; Rajeeve S
Front Oncol; 2024; 14():1398902. PubMed ID: 38800372
[TBL] [Abstract][Full Text] [Related]
20. [Current status and future prospects of immunotherapy for multiple myeloma].
Imai Y
Rinsho Ketsueki; 2021; 62(5):407-417. PubMed ID: 34108322
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
